Company: PTPI
Filing Date: 2025-03-07
Form Type: PRE 14A
Source: 0001104659-25-021794
Chunk: 28

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-07
Form: PRE 14A
Chunk 28
---
 (ii) 3.0. Accordingly, it is highly unlikely that a holder of the Series B Warrants would wish to pay an exercise price
in cash to receive one share of Common Stock when they could instead choose the alternative cashless exercise option and pay no cash to
receive three shares of Common Stock. As a result, we will likely not receive any additional funds and do not expect to receive any additional
funds upon the exercise of the Series B Warrants (the “Alternative Cashless Exercise”).

Fundamental Transactions

In the event we consummate a merger or consolidation with or into another
person or other reorganization event in which our Common Stock is converted or exchanged for securities, cash or other property, or we
sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of our assets or we or another person
acquire more than 50% of our outstanding shares of Common Stock, then following such event, the holders of the Series B Warrants
will be entitled to receive upon exercise of the Series B Warrants the same kind and amount of securities, cash or property which
the holders would have received had they exercised the Series B Warrants immediately prior to such fundamental transaction. Any successor
to us or surviving entity shall assume the obligations under the Series B Warrants. Additionally, as more fully described in the
Series B Warrants, in the event of certain fundamental transactions, the holders of the Series B Warrants will be entitled to
receive consideration in an amount equal to the Black Scholes value of Series B Warrants on the date of consummation of such transaction.

Transferability

Subject to applicable laws, a Series B Warrant may be transferred
at the option of the holder upon surrender of the Series B Warrant to us together with the appropriate instruments of transfer.

Fractional Shares

No fractional shares of Common Stock will be issued upon the exercise
of the Series B Warrants. Rather, the number of shares of Common Stock to be issued will, at our election, either be rounded up to
the next whole share or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the exercise price.

Trading Market

There is no established trading market for the Series B Warrants,
and we do not expect an active trading market to develop. We do not intend to apply to list the Series B Warrants on any securities
exchange or other trading market. Without a trading market, the